Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
efbalropendekin alfa
- Development stage
- Phase 1
- Lead developer
- Xencor
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Efbalropendekin alfa is a recombinant fusion protein consisting of a soluble interleukin-15 (IL-15) and interleukin-15 receptor alpha (IL-15Rα) heterodimer complex, fused to a half-life-extended Fc domain. It is engineered with mutations to reduce IL-15 affinity for its receptor, aiming for lower potency and therefore prolonged pharmacodynamic exposure and tolerability. Its mechanism involves stimulating the expansion and activation of T cells and natural killer (NK) cells, enhancing their cytotoxic potential against tumor cells. This agent was developed for use as an immunotherapy, notably in oncology settings such as solid tumors and multiple myeloma, and has been tested in combination with other antibodies in early-phase studies.
- Other names
- efbalropendekin alfa
02
Targets
IL2RB (IL-2 receptor beta chain)
Beyond the preview
Go deeper on efbalropendekin alfa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on efbalropendekin alfa.